stockportfolio.pro
Stocks / BIO vs CORT
BIO vs CORT
Bio-Rad Laboratories, Inc. and Corcept Therapeutics Incorporated side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Bio-Rad Laboratories, Inc. (BIO) | Corcept Therapeutics Incorporated (CORT) | |
|---|---|---|
| Market cap | $7.8B | $8.4B |
| Revenue (latest FY) | $2.58B | $761.41M |
| Net income (latest FY) | $759.90M | $98.17M |
| Revenue growth (5y CAGR) | 0.3% | 16.6% |
| Net margin | 29.4% | 12.9% |
| Return on equity | 10.2% | 15.2% |
| P/E ratio | 48.8 | 222.6 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 7 | 10 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open BIO — free Open CORT — freeFrequently asked questions
Which is bigger, BIO or CORT?
Corcept Therapeutics Incorporated is larger by market capitalization — $8.4B versus $7.8B.
Which grows faster, BIO or CORT?
Over the last five fiscal years, Corcept Therapeutics Incorporated grew revenue faster — 16.6%/yr versus 0.3%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.